[
    [
        {
            "time": "",
            "original_text": "康泰生物(300601)：业绩符合预期 新冠贡献明显增量",
            "features": {
                "keywords": [
                    "康泰生物",
                    "业绩",
                    "新冠",
                    "增量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物(300601)：业绩符合预期 新冠贡献明显增量",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601)：主业平稳 新冠疫苗贡献业绩增量",
            "features": {
                "keywords": [
                    "康泰生物",
                    "主业",
                    "新冠疫苗",
                    "业绩",
                    "增量"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物(300601)：主业平稳 新冠疫苗贡献业绩增量",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "西南证券给予康泰生物买入评级：新冠疫苗驱动业绩增长，13价获批值得期待",
            "features": {
                "keywords": [
                    "西南证券",
                    "康泰生物",
                    "买入评级",
                    "新冠疫苗",
                    "业绩增长",
                    "13价",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券给予康泰生物买入评级：新冠疫苗驱动业绩增长，13价获批值得期待",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]